Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.

The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.

The invention relates to a process for producing a Tan IIA nanoliposome system for foods and medical products, comprises: (i) preparing a dispersed phase by dissolving Tan IIA in ethanol in a Tan IIA weight:ethanol volume ratio of 8:10 by a stirrer at 300-500 rpm with heating to 40-60° C. within 4-8 hours; (ii) preparing a liposome carrier consisting of lecithin and olive oil in a ratio of 1:3 by weight by mixing in a constant temperature bath at 40-60° C. to ensure that lecithin is completely dissolved in the oil while stirring; (iii) adding the carrier to the dispersed phase in a ratio of 40:60 by weight, further heating the carrier and dispersed phase mixture to 40-60° C. and stirring at 800-1000 rpm within 1 to 2 hours; (iv) cooling the resulting mixture to 25° C. and pumping the cooled mixture, using an ultrasonic atomizer nozzle at 60 Hz (10-20 μm droplet size, 10 mL/min), into 1-1.5 L of distilled water (with the temperature of the distilled water at 25° C.) to obtain a liposome suspension-water mixture; (v) homogenizing the liposome suspension-water mixture by pumping through a high pressure homogenizer at 30 Mpa to obtain a Tan IIA nanoliposome system as a homogeneous and stable mixture with a confirmed particle size smaller than 200 nm.

The present invention relates to extracellular vesicles derived from ginger (Zingiber officinale) and a use thereof, and provides: extracellular vesicles which are derived from ginger and have anticancer activity, a pharmaceutical composition and a health functional food composition which is for preventing or treating cancer and contains the extracellular vesicles as an active ingredient. The ginger-derived extracellular vesicles can penetrate into cancer cells, have excellent anticancer activity, such as inhibiting the proliferation, infiltration and migration of cancer cells, and thus may be provided as an effective anticancer composition.

According to one embodiment, a method for manufacturing a lipid particle including a drug, the method includes cooling a solution containing the lipid particle including the drug at a rate of less than or equal to 1° C. per minute.

The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.

The present invention relates to sugar-derived catanionic surfactant vesicles comprising anti-inflammatory dendrimers and to their use as a medicament, more particularly in the treatment of psoriasis.

The present disclosure relates to a method of preparing a thin film composite layer immobilizing vesicles incorporating a transmembrane protein on a porous substrate membrane, comprising providing an aqueous solution comprising the vesicles and a di-amine or tri-amine compound, covering the surface of a porous support membrane with the aqueous solution, applying a hydrophobic solution comprising an acyl halide compound, and allowing the aqueous solution and the hydrophobic solution to perform an interfacial polymerization reaction to form the thin film composite layer.

A topical composition comprising an aqueous-based composition comprising cannabinoids, in particular cannabidiol, in niosomes having size lower than 500 nm, and at least one topically acceptable excipient, characterized in that said niosomes comprise (i) at least one linear or branched polyglycerol, esterified with saturated or monounsaturated linear fatty acids, (ii) at least one polysaccharide, and optionally (iii) at least one glycol having 4 to 16 carbon atoms.

The present disclosure provides catanionic surfactant vesicles (SVs). The vesicles may be functionalized on their outer leaflet such that they may be biologically active. The vesicles may encapsulate (at least partially in the lumen and/or at least partially in the leaflet) one or more small molecules, one or more RNAs, one or more DNAs, and/or one or more proteins/peptides. Also provided are compositions comprising the vesicles (e.g., vaccine compositions comprising the vesicles) and methods of making and using the same.